- Biopharma dealmaking in 2026: The recovery gathers speed in Q2It’s always darkest before the biotech dawn, and at no time was that more true than last summer, as biotech was experiencing a crisis of confidence. We tracked an industry-wide downturn in expect…Endpoints · 3d ago↗ source
- Vertex was only bidder for Crinetics in year's second-highest M&A premiumTo gain control of Crinetics Pharmaceuticals, Vertex Pharmaceuticals was willing to pay the second-highest premium so far in biopharma's banner year for M&A. And the Boston drugmaker was biddin…Endpoints · 3d ago↗ source
- STAT+: ‘Cochlear implant for blindness’ debuts in Europe, could launch in U.S. in 2027Science Corporation announced the European launch of its retinal implant for patients with age-related macular degeneration.